CTLA4 and cholangiocarcinoma: ICI therapy for CCA patients carries promise, given some of the tumours' immunologic features, including the expression of immune checkpoint molecules, such as PD‐L1 and cytokine T‐lymphocyte‐associated protein 4 (CTLA‐4) within the tumour microenvironment.43, 44, 45